Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies

The Lancet

Volumn 373, Issue 9671, 2009, Pages 1264-1274

  Ferguson, Mark WJ ^a,b   Duncan, Jonathan ^b,c   Bond, Jeremy ^b,d   Bush, James ^b   Durani, Piyush ^b,c   So, Karen ^b   Taylor, Lisa ^b,d   Chantrey, Jonquille ^b,c   Mason, Tracey ^b   James, Gaynor ^b   Laverty, Hugh ^b   Occleston, Nick L ^b   Sattar, Abdul ^b   Ludlow, Anna ^b   O'Kane, Sharon ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Renovo   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ULSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVOTERMIN; PLACEBO; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; EDEMA; ERYTHEMA; FEMALE; HUMAN; INJECTION SITE PAIN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SCAR FORMATION; SKIN; SKIN INCISION; SKIN SCAR; VISUAL ANALOG SCALE; WOUND CARE; WOUND HEALING;

EID: 64049103218     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60322-6     Document Type: Article

References (17)

1. Bayat A., Bock O., Mrowietz U., Ollier W.E., and Ferguson M.W. Genetic susceptibility to keloid disease: transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease. Exp Dermatol 13 (2004) 120-124
2. Meier K., and Nanney L.B. Emerging new drugs for scar reduction. Expert Opin Emerg Drugs 11 (2006) 39-47
3. Mustoe T.A., Cooter R.D., Gold M.H., et al. International clinical recommendations on scar management. Plast Reconstr Surg 110 (2002) 560-571
4. Ferguson M.W., and O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 359 (2004) 839-850
5. Shah M., Foreman D.M., and Ferguson M.W.J. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108 (1995) 985-1002
6. Ashcroft G.S., Horan M.A., and Ferguson M.W. The effects of ageing on cutaneous wound healing in mammals. J Anat 187 (1995) 1-26
7. Ashcroft G.S., Horan M.A., and Ferguson M.W. Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J Invest Dermatol 108 (1997) 430-437
8. Ashcroft G.S., Horan M.A., and Ferguson M.W. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. Lab Invest 78 (1998) 47-58
9. Bayat A., McGrouther D.A., and Ferguson M.W. Skin scarring. BMJ 326 (2003) 88-92
10. Sommerlad B.C., and Creasey J.M. The stretched scar: a clinical and histological study. Br J Plast Surg 31 (1978) 34-45
11. Duncan J.A., Bond J.S., Mason T., et al. Visual analogue scale scoring and ranking: a suitable and sensitive method for assessing scar quality?. Plast Reconstr Surg 118 (2006) 909-918
12. Bond J., Duncan J., Mason T., et al. Scar redness in humans: how long does it persist following incisional and excisional wounding?. Plast Reconstr Surg 121 (2008) 487-496
13. Whitby D.J., and Ferguson M.W. Immunohistochemical localization of growth factors in fetal wound healing. Dev Biol 147 (1991) 207-215
14. O'Kane S., and Ferguson M.W.J. Transforming growth factor betas and wound healing. Int J Biochem Cell Biol 29 (1997) 63-78
15. Singer A.J., and Clark R.A. Cutaneous wound healing. N Engl J Med 341 (1999) 738-746
16. Shah M., Foreman D.M., and Ferguson M.W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339 (1992) 213-214
17. Shah M., Foreman D.M., and Ferguson M.W. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107 (1994) 1137-1157